{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:03:06Z","timestamp":1787785386403,"version":"build-2784847793"},"reference-count":27,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Atopic dermatitis (AD) in elderly patients presents unique clinical challenges due to comorbidities, polypharmacy, and an increased risk of adverse events. Janus kinase inhibitors (JAKis) have emerged as effective oral treatments, but limited data are available for their use in older adults. Methods: A narrative review was conducted through a comprehensive search of PubMed\/MEDLINE, Ovid, Scopus, Embase, Cochrane Library, Web of Science, and Google Scholar up to July 2025. Only English-language studies evaluating abrocitinib, baricitinib, or upadacitinib in elderly patients (\u226565 years) with moderate-to-severe AD were included. Results: RCTs enrolled few elderly patients and lacked dedicated subgroup analyses. Abrocitinib showed similar efficacy in older and younger adults, but higher rates of adverse events, especially at the 200 mg dose. Real-world studies, mainly on upadacitinib, demonstrated rapid and sustained clinical improvements, including in difficult-to-treat areas. Safety outcomes were generally favorable; most adverse events were mild and manageable. Herpes zoster and hematological changes were more frequent in elderly patients, while serious cardiovascular events were rare. Conclusions: JAK inhibitors are effective therapeutic options for elderly patients with moderate-to-severe AD. Careful patient selection, dose tailoring, and close monitoring are essential. Further age-specific RCTs and long-term real-world data are needed to guide clinical practice.<\/jats:p>","DOI":"10.3390\/jcm14176327","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:51:12Z","timestamp":1757332272000},"page":"6327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5607-8877","authenticated-orcid":false,"given":"Giuseppe","family":"Lauletta","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6270-959X","authenticated-orcid":false,"given":"Daniele","family":"Cecere","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"di Vico","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2822","authenticated-orcid":false,"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-8190","authenticated-orcid":false,"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40272-022-00499-x","article-title":"Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting","volume":"24","author":"Eichenfield","year":"2022","journal-title":"Paediatr. Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/08923973.2021.1889583","article-title":"Atopic dermatitis: New insight into the etiology, pathogenesis, diagnosis and novel treatment strategies","volume":"43","author":"Mandlik","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ggi.12771","article-title":"Atopic dermatitis in older adults: A viewpoint from geriatric dermatology","volume":"16","author":"Tanei","year":"2016","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chan, L.N., Magyari, A., Ye, M., Al-Alusi, N.A., Langan, S.M., Margolis, D., McCulloch, C.E., and Abuabara, K. (2021). The epidemiology of atopic dermatitis in older adults: A population-based study in the United Kingdom. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258219"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1203475420911896","article-title":"Adult-Onset Atopic Dermatitis: Presentations and Progress","volume":"24","author":"Chan","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"adv13363","DOI":"10.2340\/actadv.v103.13363","article-title":"Atopic Dermatitis in the Elderly Population","volume":"103","author":"Maurelli","year":"2023","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: Part I\u2014Systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1080\/09546634.2022.2102121","article-title":"Dupilumab for the treatment of adult atopic dermatitis in special populations","volume":"33","author":"Patruno","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhao, K., Yang, G., Zhou, X., Yang, J., Zhao, J., Xiang, J., Chen, X., and Zhang, L. (2025). Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients with and Without Atopic Comorbidities: A Retrospective Study. Dermatitis, ahead of print.","DOI":"10.1089\/derm.2024.0402"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lauletta, G., Potestio, L., Patruno, C., Ferrucci, S.M., Angileri, L., Barei, F., Ortoncelli, M., Ribero, S., Girolomoni, G., and Malagoli, P. (2025). Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD. Dermatitis, ahead of print.","DOI":"10.1089\/derm.2025.0129"},{"key":"ref_12","first-page":"403","article-title":"Adult atopic dermatitis: A review","volume":"151","author":"Napolitano","year":"2016","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/jdv.18922","article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations","volume":"37","author":"Adam","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gatmaitan, J.G., and Lee, J.H. (2023). Challenges and Future Trends in Atopic Dermatitis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411380"},{"key":"ref_15","unstructured":"(2024, December 13). Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Philippoteaux, C., Deprez, V., Nottez, A., Cailliau, E., Houvenagel, E., Deprez, X., Philippe, P., Pascart, T., Flipo, R.M., and Go\u00ebb, V. (2022). Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010207"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: The theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","article-title":"Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review","volume":"156","author":"Lam","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","article-title":"Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)","volume":"25","author":"Silverberg","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2344589","DOI":"10.1080\/09546634.2024.2344589","article-title":"Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study","volume":"35","author":"Magnolo","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaip.2025.02.040","article-title":"Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age","volume":"13","author":"Cork","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Melgosa Ramos, F.J., Vila Cobreros, L., Pascual, M.G., Guill\u00e9n-Climent, S., Matellanes-Palacios, M., Roca Gin\u00e9s, J., Sabater-Abad, J., Bernia-Petit, E., Casanova Esquembre, A., and Est\u00e9banez Corrales, A. (2025). Effectiveness and Safety of Upadacitinib in Adults Older Than 50\u2009Years With Moderate-To-Severe Atopic Dermatitis: A Multicenter Study. Int. J. Dermatol., ahead of print.","DOI":"10.1111\/ijd.17797"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2245510","DOI":"10.1080\/09546634.2023.2245510","article-title":"Upadacitinib for the treatment of atopic dermatitis in the elderly: An Italian case series of seven patients","volume":"34","author":"Piscazzi","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-025-00923-1","article-title":"Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations","volume":"26","author":"Tong","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e15728","DOI":"10.1111\/dth.15728","article-title":"Baricitinib rapidly relieves eczema associated pruritus in elderly patients","volume":"35","author":"Hong","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00403-025-04278-9","article-title":"Efficacy and safety of JAK inhibitors in patients aged >\u200960 years with moderate-to-severe atopic dermatitis: A 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)","volume":"317","author":"Potestio","year":"2025","journal-title":"Arch. Dermatol. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:39Z","timestamp":1760035299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":27,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14176327"],"URL":"https:\/\/doi.org\/10.3390\/jcm14176327","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}